67015-06-9

Basic information

• Product Name: N-HYDROXY-PENTANAMIDINE
• Synonyms: N-HYDROXY-PENTANAMIDINE
• CAS NO: 67015-06-9
• Molecular Formula: C₅H₁₂N₂O
• Molecular Weight: 116.16158
• Product Categories: pharmacetical
• Mol File: 67015-06-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 27 °C
• Boiling Point: 176.7±23.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• PKA: 7.48±0.69(Predicted)
• CAS DataBase Reference: N-HYDROXY-PENTANAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-PENTANAMIDINE(67015-06-9)
• EPA Substance Registry System: N-HYDROXY-PENTANAMIDINE(67015-06-9)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 67015-06-9(Hazardous Substances Data)

Upstream product

• 110-59-8 pentanonitrile 

Downstream Products

• 135436-93-0 2-(3-butyl-[1,2,4]oxadiazol-5-yl)-phenylamine 
• 128105-20-4 3-n-propyl-5[(2,4-dichlorophenoxy)methyl]-1,2,4-oxadiazole 
• 844875-53-2 C₂₉H₃₅N₅O₄ 
• 110-59-8 pentanonitrile 
• 626-97-1 pentamide 
• 150694-40-9 4'-<<3-butyl-5,6-dihydro-5-oxo-6-(phenylethyl)-4H-1,2,4-oxadiazin-4-yl>methyl><1,1'-biphenyl>-2-carboxylic acid t-butyl ester 
• 150694-37-4 4'-<<3-butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl>methyl><1,1'-biphenyl>-2-carboxylic acid 
• 150694-39-6 3-butyl-6-(phenylethyl)-4H-1,2,4-oxadiazin-5(6H)-one 
• 150694-33-0 4'-<<3-butyl-5,6-dihydro-5-oxo-6-(phenylmethyl)-4H-1,2,4-oxadiazin-4-yl>methyl><1,1'-biphenyl>-2-carboxylic acid t-butyl ester 
• 150694-42-1 4'-<<3-butyl-5,6-dihydro-5-oxo-6-(2-phenylethyl)-4H-1,2,4-oxadiazin-4-yl>methyl><1,1'-biphenyl>-2-carbonitrile 
• 150694-17-0 4'-<(3-butyl-5,6-dihydro-6-methyl-5-oxo-4H-1,2,4-oxadiazin-4-yl)methyl><1,1'-biphenyl>-2-carboxylic acid 
• 150694-32-9 3-butyl-6-phenylmethyl-4H-1,2,4-oxadiazin-5(6H)-one 
• 150758-58-0 3-butyl-6-phenyl-4H-1,2,4-oxadiazin-5(6H)-one 
• 175473-44-6 4-Butyl-3-[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-[1,2,3,5]oxathiadiazole 2-oxide 

Relevant articles and documents

OXADIAZOLE COMPOUNDS

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: Discovery, SAR, modeling, and mutagenesis

Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral RNA. We recently disclosed dihydroxypyrimidine carboxylates 2 as novel, reversible inhibitors of the HCV NS5B polymerase. This series was further developed into 5,6-dihydroxy-2-(2- thienyl)pyrimidine-4-carboxylic acids such as 34 (EC50 9.3 μM), which now show activity in the cell-based HCV replication assay. The structure-activity relationship of these inhibitors is discussed in the context of their physicochemical properties and of the polymerase crystal structure. We also report the results of mutagenesis experiments which support the proposed binding model, which involves pyrophosphate-like chelation of the active site Mg ions.

NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.